---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic burden and healthcare resource utilization. Topics: Incremental annual costs of newly diagnosed gMG compared with matched controls: U.S. claims, 2017 to 2023; Costs associated with exacerbations and crises in newly diagnosed gMG: U.S. claims; Incremental costs and event-related costs in prevalent and incident gMG: U.S. claims, 2017 to 2023; Incremental monthly costs and the effect of comorbidities and acute events: U.S. claims, 2017 to 2021; 6 further topics. 10 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Incremental annual costs of newly diagnosed gMG compared with matched controls: U.S. claims, 2017 to 2023

> “Adults with newly diagnosed gMG were identified from Komodo Research data (January 1, 2017, to September 30, 2023).”
> “The gMG cohort (mean follow-up = 32.7 months) compared with the non-MG cohort (mean follow-up = 31.3 months) had 2.4, 1.6, and 1.9 times more inpatient days, emergency department visits, and outpatient visits annually, respectively (all P < 0.001).”
> “Mean annual all-cause total health care costs in the gMG cohort were $43,872 higher than in the non-MG cohort ($58,341 vs $14,469; P < 0.001); 59.3% of the difference was driven by pharmacy costs (mostly immunoglobulin).”
> “Prediagnosis weakness and fatigue symptoms, exacerbation or crisis, and use of immunoglobulin were important factors significantly associated with high health care costs in the gMG cohort (all P < 0.001).”

Source: [Grover et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13293495/)

<a id="topic-2.2.1.8.2-2"></a>

### Costs associated with exacerbations and crises in newly diagnosed gMG: U.S. claims

> “Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).”
> “After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index. Mean total healthcare costs were $70,792 higher among patients with a clinical event ($95,821 vs. $25,029, p < 0.001), driven by immunoglobulin and inpatient costs.”

Source: [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.8.2-3"></a>

### Incremental costs and event-related costs in prevalent and incident gMG: U.S. claims, 2017 to 2023

> “Analyses included 16,561 gMG patients (12,813 prevalent and 3748 incident) and 105,716 non-gMG controls. Among prevalent and incident gMG patients, respectively, MG exacerbation occurred during follow-up in 12.2 and 22.0% and myasthenic crisis in 6.0 and 12.4%.”
> “After weighting, gMG patients (median follow-up 696 days) experienced more frequent all-cause HCRU encounters and >4-fold higher healthcare costs ($5420 PPPM or ∼$65,000 per annum) versus non-gMG controls ($1298 PPPM or ∼$15,500 per annum).”
> “Among MG patients, those with MG exacerbation/myasthenic crisis, respectively, experienced means of 3.02/3.35 hospitalizations, 1.91/2.13 emergency department encounters, 12.70/13.39 skilled nursing facility encounters, and 67.86/75.52 outpatient encounters during follow-up; associated costs were $17,113/$18,640 PPPM (or ∼$205,000/$224,000 per annum).”

Source: [Jackson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41099443/)

<a id="topic-2.2.1.8.2-4"></a>

### Incremental monthly costs and the effect of comorbidities and acute events: U.S. claims, 2017 to 2021

> “The gMG and matched non-MG cohorts each contained 2,739 patients. Mean incremental healthcare costs associated with MG were $4,155 (gMG: $5,567; non-MG: $1,411), with differences driven by incremental inpatient costs of $2,166 (gMG: $2,617; non-MG: $452); all p < 0.001.”
> “Among patients with gMG in cardiometabolic (n = 1,859), psychiatric (n = 1,308), and exacerbation/crisis (n = 419) subgroups, mean monthly healthcare costs were $6,660, $7,443, and $17,330, respectively.”

Source: [Zhdanava et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38745448/)

<a id="topic-2.2.1.8.2-5"></a>

### First-year costs after diagnosis by payer: U.S. commercial and Medicare claims, 2016 to 2021

> “The final analytic cohort included 3,700 patients with MG and 37,000 controls. On average, patients were aged 54 years, with 60% being female. The difference-in-difference estimates of the total health care cost for MG diagnosis in commercial and Medicare patients were $25,799 and $4,927, respectively (P < 0.01).”

Source: [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039500/)

<a id="topic-2.2.1.8.2-6"></a>

### Costs in newly diagnosed and previously diagnosed patients and around crisis events: U.S. claims, 2014 to 2019

> “Mean HCRU and costs were higher for newly diagnosed patients compared with previously diagnosed patients (hospitalizations: 0.46 vs. 0.34; all-cause costs: $26,419.20 vs. $24,941.47; direct costs for gMG treatments: $9,890.37 vs. $9,186.47) and further increased for patients with exacerbation events (hospitalizations: 0.72; all-cause costs: $43,734.15; direct costs for gMG treatments: $21,550.02).”
> “For patients who experienced crisis events, HCRU and costs markedly increased during the 12 months immediately before the crisis event (hospitalizations: 1.35; all-cause costs: $49,236.68) compared with the 2 preceding years and increased further during the 12 months following the crisis index date (hospitalizations: 2.78; all-cause costs: $173,956.99).”

Source: [Phillips et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8805609/)

<a id="topic-2.2.1.8.2-7"></a>

### Costs in patients treated with chronic IVIg or multiple nonsteroidal immunosuppressants

> “Compared with the reference cohort (n = 2992), the MG crisis rate was approximately twice as high in both the chronic IVIg (n = 324) and multiple NSIST (n = 291) cohorts (p < 0.001); and the MG exacerbation rate was approximately four-fold higher in the chronic IVIg cohort (p < 0.001) and three-fold higher in the multiple NSIST cohort (p < 0.001).”
> “Median annual MG-related inflation-adjusted total healthcare costs were higher in the chronic IVIg ($81,900) and multiple NSIST ($30,300) cohorts than in the reference cohort ($2540).”

Source: [Parthan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38018505/)

<a id="topic-2.2.1.8.2-8"></a>

### Costs by glucocorticoid exposure: U.S. commercial claims

> “Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).”
> “Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%).”
> “Annual all-cause costs were >2x higher among patients with any GC use than those with no GC use ($76,381 vs $35,309). GC acute and chronic toxicities and costs tended to increase with increasing GC use.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="topic-2.2.1.8.2-9"></a>

### Hospitalization trends: U.S. Nationwide Inpatient Sample and Medicare, 2010 to 2019

> “Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001). Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.”
> “The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.”

Source: [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)

<a id="topic-2.2.1.8.2-10"></a>

### Range of direct and indirect costs across studies: systematic reviews

> “Across studies, the mean per-patient annual direct medical cost of illness was estimated at between $760 and $28,780, and cost per hospitalization between $2550 and $164,730. The indirect cost of illness was estimated at $80 and $3550.”
> “Costs varied considerably by patient characteristics, and drivers of the direct medical cost of illness included intravenous immunoglobulin and plasma exchange, myasthenic crisis, mechanical ventilatory support, and hospitalizations.”

Source: [Landfeldt et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32363541/)

> “1374 records were identified initially, and 44 were included in the final review.”
> “Direct costs include treatment and follow-up in the primary and specialist health care. They were estimated to €3 500–12 000 per MG patient per year in the Nordic countries, similar in other European countries, and higher in United States.”
> “Intangible costs include value of lost life-years and reduced quality of life, which are rarely assessed, but have been estimated to be half of the total societal MG costs.”

Source: [Gilhus et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13645850/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
